Clinical Research Directory

Inclusion Criteria: * Written informed consent obtained prior to the performance of any study-specific procedures. * Patients scheduled to receive curative-intent cervical radiotherapy (minimum prescribed dose of 66 Gy using standard fractionation), with or without concomitant platinum-based chemotherapy and/or cetuximab, for upper aerodigestive tract cancer. * Willingness to undergo photography of the irradiated areas at baseline, weekly during radiotherapy, and at 7 and 15 days after completion of radiotherapy. * Patient covered by a health insurance plan. Exclusion Criteria: * Known hypersensitivity or allergy to chlorhexidine or mupirocin. * Continuous long-term oxygen therapy (24 hours/day) via nasal cannula. * Previous irradiation of the treatment area. * Active chronic skin disease within the treatment field causing substantial skin changes and contraindicating the decolonization procedure, including severe inflammatory dermatoses (e.g., active psoriasis flare). * Active chronic skin disease within the treatment field causing skin changes that could interfere with the accurate assessment of radiation dermatitis (e.g., severe psoriasis or extensive inflammatory dermatoses). * Use of photobiomodulation therapy as supportive care during radiotherapy and/or within 15 days after treatment completion. * Pregnant or breastfeeding women. * Individuals deprived of liberty or under legal protection measures (guardianship, trusteeship, or equivalent legal protective supervision). * Inability to comply with study follow-up requirements for geographic, social, or psychological reasons.